Regeneron (REGN) Highlights Positive Topline Results in Phase 3 Trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. DOL:CN

Go back to Regeneron (REGN) Highlights Positive Topline Results in Phase 3 Trial

Regeneron (REGN) Tops Q2 EPS by 61c, Revenues Beat

August 6, 2019 6:43 AM EDT

Regeneron (NASDAQ: REGN) reported Q2 EPS of $6.02, $0.61 better than the analyst estimate of $5.41. Revenue for the quarter came in at $1.93 billion versus the consensus estimate of $1.8 billion.

Second quarter 2019 revenues increased 20% to $1.93 billion versus second quarter 2018EYLEA® U.S. net sales increased 17% to $1.16 billion versus second quarter 2018Dupixent® global net sales, which are recorded by the Company's collaborator Sanofi, increased 166% to $557... More

Regeneron (REGN) Reports Dupixent Granted European Commission Approval for Adolescents with Moderate-to-Severe Atopic Sermatitis

August 6, 2019 5:57 AM EDT

Renegeron (NASDAQ: REGN) announced the European Commission (EC) today extended the marketing authorization for Dupixent® (dupilumab) in the European Union (EU) to include adolescents 12 to 17 years of age with moderate-to-severe atopic dermatitis who are candidates for systemic therapy. Dupixent is now the first biologic medicine approved in the EU to treat these patients.

Moderate-to-severe atopic dermatitis can affect many aspects of an adolescents life, including their physical and emotional well-being, said Christine Janus, Chief Executive Officer of the International Alliance of Dermatology Patient... More